Authors:
Geary, RS
Khatsenko, O
Bunker, K
Crooke, R
Moore, M
Burckin, T
Truong, L
Sasmor, H
Levin, AA
Citation: Rs. Geary et al., Absolute bioavailability of 2 '-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats, J PHARM EXP, 296(3), 2001, pp. 898-904
Authors:
Yu, RZ
Zhang, H
Geary, RS
Graham, M
Masarjian, L
Lemonidis, K
Crooke, R
Dean, NM
Levin, AA
Citation: Rz. Yu et al., Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice, J PHARM EXP, 296(2), 2001, pp. 388-395
Authors:
Yu, RZ
Geary, RS
Leeds, JM
Watanabe, T
Moore, M
Fitchett, J
Matson, J
Burckin, T
Templin, MV
Levin, AA
Citation: Rz. Yu et al., Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey, J PHARM SCI, 90(2), 2001, pp. 182-193
Authors:
Cunningham, CC
Holmlund, JT
Geary, RS
Kwoh, TJ
Dorr, A
Johnston, JF
Monia, B
Nemunaitis, J
Citation: Cc. Cunningham et al., A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma, CANCER, 92(5), 2001, pp. 1265-1271
Authors:
Geary, RS
Yu, RZ
Leeds, JM
Watanabe, TA
Henry, SP
Levin, AA
Templin, MV
Citation: Rs. Geary et al., Pharmacokinetic properties in animals, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 119-154
Authors:
Templin, MV
Levin, AA
Graham, MJ
Aberg, PM
Axelsson, BI
Butler, M
Geary, RS
Bennett, CF
Citation: Mv. Templin et al., Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotidefollowing inhalation delivery to lung in mice, ANTISENSE N, 10(5), 2000, pp. 359-368
Authors:
Khatsenko, O
Morgan, R
Truong, L
York-Defalco, C
Sasmor, H
Conklin, B
Geary, RS
Citation: O. Khatsenko et al., Absorption of antisense oligonucleotides in rat intestine: Effect of chemistry and length, ANTISENSE N, 10(1), 2000, pp. 35-44
Authors:
Cunningham, CC
Holmlund, JT
Schiller, JH
Geary, RS
Kwoh, TJ
Dorr, A
Nemunaitis, J
Citation: Cc. Cunningham et al., A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer, CLIN CANC R, 6(5), 2000, pp. 1626-1631
Authors:
Yuen, AR
Halsey, J
Fisher, GA
Holmlund, JT
Geary, RS
Kwoh, TJ
Dorr, A
Sikic, BI
Citation: Ar. Yuen et al., Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer, CLIN CANC R, 5(11), 1999, pp. 3357-3363
Authors:
Yu, RZ
Geary, RS
Leeds, JM
Watanabe, T
Fitchett, JR
Matson, JE
Mehta, R
Hardee, GR
Templin, MV
Huang, K
Newman, MS
Quinn, Y
Uster, P
Zhu, G
Working, PK
Horner, M
Nelson, J
Levin, AA
Citation: Rz. Yu et al., Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes, PHARM RES, 16(8), 1999, pp. 1309-1315
Citation: Rs. Geary et al., A nonradioisotope biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue, ANALYT BIOC, 274(2), 1999, pp. 241-248
Authors:
Monteith, DK
Geary, RS
Leeds, JM
Johnston, J
Monia, BP
Levin, AA
Citation: Dk. Monteith et al., Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys, TOXICOL SCI, 46(2), 1998, pp. 365-375